Galliprant® (grapiprant) is a new class of anti-inflammatories approved for the treatment of osteoarthritis in dogs. Unlike classic NSAIDs, Galliprant does not affect cyclooxygenases (COX) in the arachidonic acid pathway. Instead, Galliprant blocks a prostaglandin-specific receptor called the EP4 receptor, which is a key mediator of pain and inflammation induced by osteoarthritis in dogs. Since Galliprant does not cause COX inhibition, most of the undesirable side effects on the gastrointestinal tract and kidneys seen with traditional NSAIDs can be avoided.

Accessed 2017-08-15 from

Dosage Forms

  • Tablet sizes: 20mg, 60mg, 100mg. The tablets are scored and can be broken in half.


  • 2 mg/kg orally once daily
  • Give on an empty stomach – dosing with food reduces bioavailability


  • Approved for use in dogs older than 9 months and larger than 8 pounds
  • Use in the following groups has not been evaluated: pain for reasons other than osteoarthritis, dogs intended for breeding, pregnancy, lactation, cardiac disease, sensitivity to sulfonamides
  • Use of concurrent steroids and NSAIDs should be avoided with Galliprant
  • NOT for use in cats


Product Insert – Galliprant – Accessed 7-2017


  1. Kirkby Shaw, K., Rausch-Derra, L., and Rhodes, L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet. Med. Sci. 2106;2:3-9. Download full-text article
  2. Rausch-Derra, L., Huebner, M., Wofford, J., et al. A prospective, randomized, masked, placebo controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. J. Vet. Int. Med. 2016;30: 756-763. Download full-text article

Additional resources

Last updated: 2017-08-15